Login to Your Account



Clinic Roundup


Friday, September 2, 2011
MorphoSys AG, of Martinsried, Germany, said it dosed the first patient in a Phase I/IIa trial testing the safety and preliminary efficacy of anti-CD38 cancer antibody MOR202 in patients with relapsed or refractory multiple myeloma. The study is expected to enroll a maximum of 82 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription